Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 13/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13738280 | 0.82 | METAP2 (0.45) | METAP2KCNH2ERAP1ACLYEPHX2 | |
| SCHEMBL13739016 | 0.81 | METAP2 (0.59) | METAP2 | |
| SCHEMBL13739015 | 0.81 | METAP2 (0.59) | METAP2 | |
| SCHEMBL13738359 | 0.80 | METAP2 (0.44) | METAP2GAAMAPK1 | |
| SCHEMBL3988647 | 0.77 | METAP2 (0.55) | METAP2 | |
| SCHEMBL13739197 | 0.74 | METAP2 (0.43) | METAP2KCNH2ERAP1ACLYEPHX2 | |
| SCHEMBL13740004 | 0.74 | METAP2 (0.48) | METAP2KCNH2ACLYCMA1GAA | |
| SCHEMBL13740925 | 0.73 | METAP2 (0.43) | METAP2KCNH2ERAP1ACLYEPHX2 | |
| SCHEMBL13739990 | 0.72 | METAP2 (0.67) | METAP2 | |
| SCHEMBL13739989 | 0.72 | METAP2 (0.67) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561230-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561230-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561230-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9187494-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187494-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187494-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2705036-B1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2705036-B1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2705036-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012154678-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154678-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | DNPEP, METAP2, ANPEP | METAP2 2/4885KCNH2 2938/4885ERAP1 47/4885 |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, METAP2, ANPEP | METAP2 2/4885KCNH2 2938/4885ERAP1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.